Jad Othman, MBBS, King’s College and Guy's & St Thomas' NHS Foundation Trust, London, UK, speaks on measurable residual disease (MRD)-guided salvage treatment with FLT3 inhibitors for patients with molecular failure in FLT3-mutated acute myeloid leukemia (AML). Using MRD positivity to guide administration, FLT3 inhibitors demonstrate high response rates. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
